On September 26, Forbes China officially released the "2024 ESG Inspirational Cases". Sino Biopharm stood out from over 500 outstanding ESG cases from competing companies across all industries for its excellent practical performance in the integration of digitalization and ESG, becoming one of the 10 most representative ESG inspirational cases.

The 2024 ESG Inspirational Cases is the first ESG practical case study selection for Chinese enterprises initiated by Forbes China, dedicated to identifying leading ESG practitioners in China and providing inspiration and reference for corporate ESG practices. In this research and analysis, Forbes China emphasized the integration of the ESG concept with a company's core business, development strategy, and business model, and explored innovative ways and models for implementing ESG with an innovative mindset. Being selected for the "Forbes ESG Inspirational Cases" represents Forbes China's full affirmation of Sino Biopharm's effective integration of ESG practices with its corporate development strategy.

As a leading innovation and R&D-driven pharmaceutical group in China, Sino Biopharm has always insisted on the deep integration and resonance of the ESG concept with its corporate operations. As one of the four core strategies being deeply promoted, the Group places great importance on the deep integration of digitalization and ESG. On one hand, we continuously explore the application of digital and intelligent technologies throughout the entire lifecycle of drug R&D and production, thereby effectively enhancing medical accessibility and seeking health and well-being for more patients. On the other hand, Sino Biopharm has introduced intelligent equipment and an "ESG Smart Management Platform" to achieve efficient resource utilization and precise management of ESG data, reducing operational costs and enhancing ESG decision-making capabilities.

Through the integration of digitalization and ESG, Sino Biopharm has achieved significant results in multiple aspects. In terms of the environment, the company has utilized digital means to optimize production processes and management, significantly reducing energy consumption and greenhouse gas emission intensity. In the social aspect, with the help of digital platforms, the company's drug R&D efficiency has continuously improved, and communication and management with stakeholders such as suppliers and employees have become more convenient and efficient. In terms of governance, the company uses digital tools to enhance decision-making efficiency and transparency, strengthen internal management and risk control, and ensure stable corporate operations.

In the future, Sino Biopharm will continue to integrate the ESG concept into the main aspects of its corporate operations. Through high-quality ESG management, it will earnestly practice the Group's mission of "improving the quality and protecting the dignity of human life", seek health and well-being for more patients, and contribute to the sustainable development of the industry and even the nation.

On September 26, Forbes China officially released the "2024 ESG Inspirational Cases". Sino Biopharm stood out from over 500 outstanding ESG cases from competing companies across all industries for its excellent practical performance in the integration of digitalization and ESG, becoming one of the 10 most representative ESG inspirational cases.

The 2024 ESG Inspirational Cases is the first ESG practical case study selection for Chinese enterprises initiated by Forbes China, dedicated to identifying leading ESG practitioners in China and providing inspiration and reference for corporate ESG practices. In this research and analysis, Forbes China emphasized the integration of the ESG concept with a company's core business, development strategy, and business model, and explored innovative ways and models for implementing ESG with an innovative mindset. Being selected for the "Forbes ESG Inspirational Cases" represents Forbes China's full affirmation of Sino Biopharm's effective integration of ESG practices with its corporate development strategy.

As a leading innovation and R&D-driven pharmaceutical group in China, Sino Biopharm has always insisted on the deep integration and resonance of the ESG concept with its corporate operations. As one of the four core strategies being deeply promoted, the Group places great importance on the deep integration of digitalization and ESG. On one hand, we continuously explore the application of digital and intelligent technologies throughout the entire lifecycle of drug R&D and production, thereby effectively enhancing medical accessibility and seeking health and well-being for more patients. On the other hand, Sino Biopharm has introduced intelligent equipment and an "ESG Smart Management Platform" to achieve efficient resource utilization and precise management of ESG data, reducing operational costs and enhancing ESG decision-making capabilities.

Through the integration of digitalization and ESG, Sino Biopharm has achieved significant results in multiple aspects. In terms of the environment, the company has utilized digital means to optimize production processes and management, significantly reducing energy consumption and greenhouse gas emission intensity. In the social aspect, with the help of digital platforms, the company's drug R&D efficiency has continuously improved, and communication and management with stakeholders such as suppliers and employees have become more convenient and efficient. In terms of governance, the company uses digital tools to enhance decision-making efficiency and transparency, strengthen internal management and risk control, and ensure stable corporate operations.

In the future, Sino Biopharm will continue to integrate the ESG concept into the main aspects of its corporate operations. Through high-quality ESG management, it will earnestly practice the Group's mission of "improving the quality and protecting the dignity of human life", seek health and well-being for more patients, and contribute to the sustainable development of the industry and even the nation.